Tweet 
Advisors Asset Management Inc. raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 8.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,314 shares of the company's stock after acquiring an additional 1,183 shares during the quarter. Advisors Asset Management Inc.'s holdings in Zoetis were worth $976,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 
Other institutional investors have also modified their holdings of the company. Ironwood Investment Management LLC lifted its stake in shares of Zoetis by 0.7% during the 2nd quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company's stock valued at $429,000 after buying an additional 48 shares in the last quarter. Wilbanks Smith & Thomas Asset Management LLC lifted its stake in shares of Zoetis by 1.8% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company's stock valued at $354,000 after buying an additional 98 shares in the last quarter. First Manhattan Co. lifted its stake in shares of Zoetis by 1.1% during the 2nd quarter. First Manhattan Co. now owns 9,099 shares of the company's stock valued at $567,000 after buying an additional 99 shares in the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Zoetis by 1.3% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 7,795 shares of the company's stock valued at $486,000 after buying an additional 100 shares in the last quarter. Finally, Scotia Capital Inc. lifted its stake in shares of Zoetis by 1.5% during the 2nd quarter. Scotia Capital Inc. now owns 9,628 shares of the company's stock valued at $601,000 after buying an additional 142 shares in the last quarter. Institutional investors and hedge funds own 93.33% of the company's stock. Get Zoetis Inc. alerts: 
Shares of Zoetis Inc. ( NYSE:ZTS ) remained flat at $$72.30 during midday trading on Friday. 1,930,000 shares of the company's stock were exchanged, compared to its average volume of 2,476,389. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The company has a market capitalization of $35,230.95, a P/E ratio of 33.17, a P/E/G ratio of 2.17 and a beta of 1.06. Zoetis Inc. has a 52 week low of $48.54 and a 52 week high of $72.71. Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. Zoetis's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 EPS. analysts forecast that Zoetis Inc. will post 2.37 EPS for the current year. 
The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were issued a $0.105 dividend. The ex-dividend date of this dividend was Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.58%. Zoetis's dividend payout ratio (DPR) is presently 22.11%. 
A number of research firms recently weighed in on ZTS. Zacks Investment Research upgraded shares of Zoetis from a "hold" rating to a "buy" rating and set a $71.00 target price on the stock in a research note on Thursday, October 12th. Cantor Fitzgerald restated a "buy" rating and set a $75.00 target price on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a "hold" rating to a "sell" rating in a research note on Friday, October 6th. Morgan Stanley lifted their target price on shares of Zoetis from $61.00 to $70.00 and gave the company an "equal weight" rating in a research note on Friday, November 3rd. Finally, Goldman Sachs Group restated a "neutral" rating and set a $62.00 target price on shares of Zoetis in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company's stock. The company currently has an average rating of "Buy" and an average price target of $68.24. 
Zoetis Company Profile 
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.   Zoetis Inc.   Zoetis Inc.
